LIfT BioSciences Announces CEO Transition to Drive Next Phase of Growth with Neutrophil-based Therapies

- Dr. Bo Rode Hansen, current Board member and Corporate Development Officer

named Interim CEO

- Alex Blyth, Founder and CEO to step down and will continue to work with the Company

at a Board level

- LIfT BioSciences is currently advancing its first IMAN-based product and preparing to

initiate a first-in-human Phase 1 clinical trial. This groundbreaking next-generation

immunotherapy aims to target patients with treatment-resistant cancers.

London, January 7, 2026 – LIfT BioSciences (‘LIfT’ or ‘the Company’) today announced the

appointment of accomplished biopharmaceutical executive Bo Rode Hansen, PhD, as interim

Chief Executive Officer (CEO), effective as of today. He is succeeding founder and outgoing CEO

Alex Blyth, who has stepped down and in future will serve as a Board Director. Dr. Hansen, a

member of the LIfT Board and the Company’s Corporate Development Officer, assumes the

interim CEO role as LIfT enters its next phase of growth as a clinical-stage company. The Board

sincerely thanks Alex for his pioneering leadership in founding LIfT and advancing its neutrophil based

therapies toward the clinic and is excited that Dr. Hansen will provide strong interim

leadership as the Company moves to its next level of development.

Bo brings more than 20 years of transformational leadership experience at global

pharmaceutical and biotechnology companies, including Roche, Genevant and Santaris

Pharma. He has a successful track record of building and leading both private and public

biopharmaceutical innovators and has also served as an Entrepreneur in Residence at Biorigin,

Novo Seeds (Novo Holdings). His expertise will support LIfT BioSciences as it pioneers a new

class of immunotherapy based on its proprietary allogeneic Immuno-Modulatory Alpha

Neutrophils (IMANs)®. The Company’s lead programme is on track to enter a Phase 1 clinical trial

in cervical cancer and head and neck cancer in early 2027.

“LIfT has developed the world’s only long-lived, off-the-shelf neutrophil-based immunotherapy

backed by robust preclinical data demonstrating IMANs’ potential to penetrate solid tumours

and their inherent dual mechanism of cytotoxicity and potent immunomodulatory effects,” said

Dr. Bo Rode Hansen, interim Chief Executive Officer at LIfT BioSciences. “With the promise

of our preclinical data and as we prepare for clinical development, I look forward to working with

the talented team at LIfT to unlock a new frontier in solid tumour immunotherapy and potentially

reshape outcomes for patients who currently have limited options.”

“Bo’s outstanding track record in leading and building cutting-edge life science companies

brings tremendous value to LIfT. His strategic insights and business leadership come at the right

time as we prepare for the next stage of clinical development,” said Antonin de Fougerolles,

Chairman of the Board at LIfT BioSciences. “I would also like to thank Alex, whose vision and

leadership have been pivotal in establishing LIfT and advancing neutrophil-based therapies

towards the clinic. Together with the Board, I look forward to continuing our work and bringing

this potentially transformative therapy one step closer to the patients.”

Dr. Hansen has held key global executive positions and Board roles, contributing significantly to

company growth through strategic planning across immunology, oncology, and rare disease

indications. Dr. Hansen joined LIfT’s Board of Directors as a Non-Executive Director and

currently serves as Chairman of the Board at TECregen and Heqet Therapeutics, as well as a

Member and Executive Advisor on the Board at Spirea Ltd. He previously held several leadership

positions, including serving as CEO and President of Scandion Oncology and as CEO and

Founding President of Genevant Sciences. He was Global Head of RNA Therapeutics at Roche

pRED, CEO and GM of Roche Innovation Centre Copenhagen, and Vice President of Drug

Discovery & Alliance at Santaris Pharma (acquired by Roche). Dr. Hansen holds a PhD in

Biochemistry from the University of Copenhagen and an MBA from Henley Business School.

About LIfT BioSciences

LIfT BioSciences is pioneering a new class of immunotherapy for hard-to-treat cancers based

on allogeneic Immuno-Modulatory Alpha Neutrophils (IMANs)®. Our proprietary, long-lived

IMANs harness neutrophils’ innate tumour-homing and infiltrating attributes, combined with

their ability to directly kill cancer cells and safely orchestrate broader immune responses,

oHering a powerful and antigen-agnostic treatment option to overcome cancer resistance

mechanisms, like suppressive tumour environment and immune evasion. Backed by deep

neutrophil biology expertise and a scalable manufacturing process, LIfT’s platform represents a

one-of-a-kind opportunity to reshape medicine and drive forward a pipeline of new therapeutics

with major impact for patients.

For more information, please contact:

LIfT BioSciences

Bo Rode Hansen

Email: info@LIfTBioSciences.com

Media enquiries

Trophic Communications

Jacob Verghese

Phone: +49 151 7441 6179

Email: LIfT@trophic.eu